Raqia Therapeutics is an exciting startup company developing a transformative chimeric antigen receptor (CAR) technology for immunotherapy. At Raqia Therapeutics, they are motivated to bring life-changing therapy to patients with cancer.

Biotechnology

Raqia Therapeutics

Raqia Therapeutics' headquarters in Boston, MA, United States

Fred Mermelstein

Alberto Nobili

Julia A. Novina

Nikhil Munshi

Marc A. Cohen

Carl Novina

Kenneth Anderson

Alain Cohen

Steven Neier

Drew Dennison

Malcolm Salter

Bruce Evans

The Research and Development team at Raqia Therapeutics is dedicated to innovating and advancing chimeric antigen receptor (CAR) technologies for cancer immunotherapy. This skilled team collaborates on designing and optimizing therapeutic candidates, conducting preclinical studies, and ensuring scientific rigor in all development phases to bring transformative therapies from the lab to patients in need.

Research and Development

The Leadership Team at Raqia Therapeutics is responsible for setting the strategic direction and vision of the company, guiding the development of innovative CAR technology for cancer immunotherapy. They oversee key operational areas, including scientific research, legal compliance, and corporate governance, ensuring that Raqia Therapeutics remains focused on delivering transformative therapies to patients effectively and ethically.

Leadership Team

��

Raqia Therapeutics

Org chart

Board & advisors

Teams

Research and Development

Leadership Team

Offices

��������

Raqia Therapeutics

Org chart

Board & advisors

Teams

Research and Development

Leadership Team

Offices

Related companies

��